Skip to main content

Edurant a New HIV Treatment Approved by FDA

  • Synopsis: Published: 2011-05-20 - Edurant is used in combination with other anti-retroviral drugs for the treatment of HIV 1 infection in adults. For further information pertaining to this article contact: U.S. Food and Drug Administration.

Main Document

The U.S. Food and Drug Administration today approved Edurant (rilpivirine) in combination with other anti-retroviral drugs for the treatment of HIV-1 infection in adults who have never taken HIV therapy (treatment-naive).

Edurant belongs to a class of HIV drugs called non-nucleoside reverse transcriptase inhibitor (NNRTI). The drug works by blocking HIV viral replication. Edurant is to be used as part of a highly active anti-retroviral therapy (HAART) regimen that is designed to suppress the amount of HIV (viral load) in the blood. Edurant is a pill taken once a day with food.

"Patients may respond differently to various HIV drugs or experience varied side effects. FDA's approval of Edurant provides an additional treatment option for patients who are starting HIV therapy," said Edward Cox, M.D., M.P.H, director, Office of Antimicrobial Products in the FDA's Center for Drug Evaluation and Research.

The safety and effectiveness of Edurant is based on 48-week data from two Phase 3 clinical trials with 1,368 adult subjects with HIV infection, and from a 96-week (with extension to 192 weeks) trial. Patients had not received prior HIV therapy and were selected to receive treatment with Edurant or efavirenz (another FDA-approved NNRTI for the treatment of HIV infection). Both drugs were given in combination with other anti-retroviral drugs.

Edurant was as effective as efavirenz in lowering viral load. In the Edurant and efavirenz groups, 83 percent and 80 percent of subjects, respectively, had undetectable amounts of HIV in their blood after 48 weeks of treatment. Patients receiving Edurant who had a higher viral load at the start of therapy were more likely not to respond to the drug than were patients with a lower viral load at the start of therapy. In addition, persons who failed therapy with Edurant developed more drug resistance than patients who failed efavirenz.

The most commonly reported side effects in patients taking Edurant included depression, difficulty sleeping (insomnia), headache and rash. Fewer patients stopped taking the drug due to side effects as compared to patients taking efavirenz.

Edurant does not cure HIV infection. Patients must stay on continuous HIV therapy to control HIV infection and decrease HIV-related illnesses.

Edurant is manufactured by Raritan, N.J.-based Tibotec Therapeutics, a division of Centocor Ortho Biotech Inc.

For more information:

FDA: HIV and AIDS Activities

www.fda.gov/ForConsumers/byAudience/ForPatientAdvocates/HIVandAIDSActivities/default.htm

FDA: Anti-retroviral drugs used in the treatment of HIV infection

www.fda.gov/ForConsumers/ByAudience/ForPatientAdvocates/HIVandAIDSActivities/ucm118915.htm

CDC: HIV/AIDS

www.cdc.gov/hiv/default.htm

HHS: AIDS News and Resources

www.aids.gov/

AIDS Information

www.aidsinfo.nih.gov/

The FDA, an agency within the U.S. Department of Health and Human Services, protects the public health by assuring the safety, effectiveness, and security of human and veterinary drugs, vaccines and other biological products for human use, and medical devices. The agency also is responsible for the safety and security of our nation's food supply, cosmetics, dietary supplements, products that give off electronic radiation, and for regulating tobacco products.

Related Information:

  1. HIV and Aids Symptoms, Information and Treatment
  2. FDA Approved Drugs that May Fight HIV
  3. Many People with HIV Start Treatment Too Late


Information from our FDA: New Drug & Product Approvals section - (Full List).


     What will I receive?

Loan Information for low income singles, families, seniors and disabled. Includes home, vehicle and personal loans.


Famous People with Disabilities - Well known people with disabilities and conditions who contributed to society.


List of awareness ribbon colors and their meaning. Also see our calendar of awareness dates.


Blood Pressure Chart - What should your blood pressure be. Also see information on blood group types and compatibility.


  1. Medicare Part B Increase Will Consume Retirees Entire COLA
  2. Organizations at High Risk from Cyber Attacks - Common Attack Methods Still Successful
  3. New Approach to Studying Chromosomes' Centers May Reveal Link to Down Syndrome and More
  4. Social Mobile Gaming Boosts Rehabilitation for Patients with Physical Disabilities




Citation